A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies
Open Access
- 25 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 13 (1), 152
- https://doi.org/10.1186/1471-2407-13-152
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvestigational New Drugs, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and LymphomasClinical Cancer Research, 2011
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT SignalingPLOS ONE, 2011
- A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- Special Symposium: Targeting molecular pathways in the jungle of soft tissue sarcoma histologyAnnals of Oncology, 2010
- Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2010
- Hsp90 and co‐chaperones twist the functions of diverse client proteinsPeptide Science, 2009
- Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V MutationClinical Cancer Research, 2008
- The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functionsFEBS Letters, 2007